Enzo Biochem's Life Sciences Unit Introduces Novel System for Simultaneous Live-Cell Imaging of Nuclear Components
New System Adds to Company's Investigative and Analytical Research Products
FARMINGDALE, N.Y.--(BUSINESS WIRE)-- Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has added a novel new system to its CELLestial(TM) line of live cell analysis products, providing expanded capability to simultaneously image both the nucleus and the nucleolus in living cells, the Company announced today. Called the Total Nuclear-ID(TM) Green/Red Nucleolar/Nuclear Detection Kit, the new addition has been specifically optimized for demanding live cell microscopy applications.
The new system was featured in a recent issue of the publication "Microscopy Today," in an article entitled "Red/Green Dual Fluorescence Detection of Both the Nucleus and Nucleolus in Living Cells." In addition, Wayne Patton, Ph.D., Chief Scientific Officer for Enzo Life Sciences, presented a poster at the prestigious Microscopy and Microanalysis 2009 conference, held recently in Richmond, VA, on the utility of the kit for various drug discovery and basic cell biology applications.
"This complete system adds significant capabilities to our growing portfolio of live cell fluorescent probes to address unmet investigator needs," said Dr. Patton. "The CELLestial(TM) product line encompasses a range of products optimized for various instrument platforms, including microscopes, microplate readers, flow cytometers and laser-scanning cytometers. Its introduction underscores our continuing commitment to introducing novel assay technologies that address rapidly expanding research fields and core applications in the Life Sciences."
The system contains proprietary dyes that are highly resistant to photobleaching and concentration quenching, ensuring strong, consistent fluorescence signal, even after extended viewing periods. It has been validated for use in live cell imaging applications, demonstrating appropriate response to treatment with well-characterized nucleolus-perturbing drugs. Potential applications for this kit include monitoring impaired ribosome biogenesis, inhibition of transcription, cell cycle dynamics and cellular stress, as well as the distribution, trafficking and dynamics of nucleolar proteins, the distribution of viral proteins, and potentially as an aid in identifying neoplastic cells.
As a world leader in non-radioactive probe technology, Enzo has now developed a wide range of products for the study of nucleic acids, as well as cellular components.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo's Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo's Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company's technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 240 patents worldwide, and has pending applications for over 200 more. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
Source: Enzo Biochem, Inc.
Released September 17, 2009